Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samuraciclib + Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT07665684Phase 2Not yet recruiting
- Sponsor
- University Health Network
- Start
- Jul 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 2 trial of samuraciclib in pancreatic ductal adenocarcinoma (PDAC), sponsored by University Health Network. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
samuraciclib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07665684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665684.